The panelists discuss how diagnosis and treatment of multiple myeloma might vary within different patient populations. They also analyze the costs associated with care for the disease within different populations.
The panelists discuss how diagnosis and treatment of multiple myeloma might vary within different patient populations. They also analyze the costs associated with care for the disease within different populations.
Dr Kumar questions the ROI for different treatments, as well as for the side effects associated with their administration. He says it’s important to identify those patients who will benefit the most from the most expensive emerging agents.
Ms Young agrees, suggesting that treatment should be personalized to each specific patients’ needs. Managing toxicities may also result in cost savings. Ms Young further suggests that clinical trials hold potential that is beneficial for determining cost-effective treatment plans in targeted patient groups.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More